A Phase II Trial Evaluating the Safety of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia

LESSONS LEARNED. Ofatumumab infusion reactions can be diminished by escalating the dose rate in individual patients in sequential infusions. BACKGROUND. Ofatumumab (OFA) is a fully humanized, anti‐CD20 antibody approved for use in chronic lymphocytic leukemia (CLL). The recommended administration re...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Donnellan, William, Berdeja, Jesus G., Shipley, Diana, Arrowsmith, Edward R., Wright, David, Lunin, Scott, Brown, Richard, Essell, James H., Flinn, Ian W.
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2017
Matèries:
Clinical Trial Results
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5634770/
https://ncbi.nlm.nih.gov/pubmed/28687625
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0236
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars